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Abstract 
Background: Antibiotic resistance due to the presence of extended‑spectrum beta‑lactamases (ESBLs) among 
Enterobacteriaceae is a worldwide problem. Data from Ghana regarding this resistance mechanism is limited. This 
study was designed to investigate the presence of TEM‑type ESBL genes, their locations and their conjugabilities in 
clinical isolates of enterobacteria collected from the Korle‑Bu Teaching Hospital in Ghana.
Methods: Study isolates were characterized with respect to ESBL phenotype, TEM‑type ESBL gene detection, loca‑
tion of the ESBL gene(s) and conjugability of the ESBL phenotype using nalidixic acid‑resistant Escherichia coli K‑12 
as recipient. Phenotyping was by Kirby Bauer disk diffusion using cefpodoxime, ceftazidime, cefotaxime and their 
combinations with clavulanate. Gene detections were by PCR using blaTEM primers.
Results: Overall, 37.96 % of 137 clinical isolates showed ESBL phenotype. The ESBLs occurred mostly in Klebsiella spp. 
(42.3 %) and then Escherichia coli (34.6 %). The TEM gene was detected in 48.1 % of ESBL‑positive isolates and was 
determined to be plasmid‑borne in 24 of 25 blaTEM detections. Overall, 62.7 % of TEM‑producing isolates transferred 
the ESBL phenotype by conjugation.
Conclusions: The results highlight the presence of TEM‑type ESBLs in the Korle‑Bu Teaching Hospital and show 
considerable risk of environmental contamination through the urine of infected persons. An inhibition zone chart was 
generated which indicates the possible presence of complex beta‑lactamase types. The data points to the fact that 
the ESBL‑producing bacteria may disseminate this resistance mechanism via conjugation.
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Background
The Enterobacteriaceae comprise a large family of clini-
cally significant Gram-negative bacteria. They cause 
over 30  % of the morbidity and mortality associated 
with bacterial infections [1, 2] [CDC 2015, unpublished 
observation]. Resistance to β-lactam antimicrobials in 
Enterobacteriaceae has been due to largely the presence 
of β-lactamase enzymes [3, 4]. β-lactamase genes (bla) 
were originally found to be chromosomal [5]. Since 
the emergence of the first reports on plasmid-borne 
blaTEM-1 in the 1960s, many more which appear to be 
mutants of the classic TEM genes, as well as novel types 
including SHV, CTX-M and OXA, have been found [6–
8]. β-lactamase-mediated resistance may develop in vivo 
during chemotherapy, lending support to the prevalent 
view that ESBL plasmids are conjugative, may be borne 
on transposons, and that the genes may have high muta-
tion frequencies [9, 10]. Also of concern is the increasing 
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dissemination of ESBLs across hitherto wildtype species 
[11].
ESBL-producing bacterial isolates have been reported 
across Africa, even in isolated remote communities [11–
16]. Beyond detection, data on specific identification of 
ESBLs are needed for deciding local therapy options, 
control strategies and recognition of unusual cases. In 
Ghana, investigations into mechanisms of β-lactam 
resistance have often been limited to phenotypic charac-
terizations. This study reports the presence of TEM-type 
β-lactamase genes, their location(s) and their transfer-
ability by conjugation in clinical enterobacteria isolates 
collected at the Korle-Bu Teaching Hospital (KBTH).
Methods
Study isolates
Bacteria were isolated from clinical specimen (sputum, 
blood, feces, urine, cerebrospinal fluid, high vaginal 
swabs, wound swabs, pus) submitted to the Microbiol-
ogy Laboratory of Korle-Bu Teaching Hospital (KBTH). 
A total of 137 isolates were included in the study. The 
isolates comprised only those recovered as members of 
the family Enterobacteriaceae [17] and identified as being 
responsible for patients’ clinical conditions. Conclusive 
identification of isolates was done with API 20E rapid test 
strips (bioMerieux SA, Marcy l’Etoile, France). Isolates 
were stocked in Luria–Bertani (LB)-ampicillin (60  μg/
ml) broth containing 15  % glycerol and kept at −20  °C. 
All stocks were routinely plated to check for purity. Four 
National Collection of Typed Cultures (NCTC) isolates 
were included in the study as controls; NCTC 10418 
(β-lactamase negative), NCTC 13352 (TEM 10 posi-
tive), NCTC 13353 (CTX-M-15 positive), NCTC 165032 
(SHV-3).
Detection of ESBL phenotype
Isolates were examined for ESBL phenotype by the 
Kirby-Bauer disk diffusion method of susceptibility test-
ing and according to United Kingdom Health Protection 
Agency (HPA) guidelines (QSOP 51i2.2, 2008). Screening 
and confirmatory tests were done simultaneously on the 
same plate. Briefly, each test isolate was plated on Muel-
ler–Hinton agar (Oxoid, UK). After incubating overnight 
at 37  °C, a 0.5 McFarland suspension in peptone broth 
(MAST, UK) of each was prepared. This suspension was 
then swabbed onto a cation-balanced Mueller–Hinton 
agar plate (MAST, UK) and left to dry completely. Anti-
biotic discs from a D52C ESBL detection kit (MAST, UK) 
were applied onto the plate and the setup was incubated 
at 37  °C for 18 h. Discs used were cefpodoxime (10 μg), 
ceftazidime (30 μg), cefotaxime (30 μg) and combination 
discs of cefotaxime/clavulanate (30/10  μg) and ceftazi-
dime/clavulanate (30/10 μg). After incubation, inhibition 
zone diameters were measured and interpreted. A zone 
difference of ≥5 mm between the single and the combi-
nation disks for any of the antibiotics was regarded posi-
tive for ESBL production. Klebsiella pneumoniae ATCC 
700603 was used as positive control for ESBL production.
Assessment of antibiotics for ESBL phenotyping
The diagnostic performance of each antibiotic used for 
ESBL phenotyping was assessed on the following criteria: 
sensitivity, specificity, positive predictive value (PPV) and 
negative predictive value (NPV).
Conjugation study
Only isolates confirmed as ESBL-producers were 
included in subsequent experiments. Conjugations were 
done using nalidixic acidR E. coli K-12 as the recipient 
strain. Three of the study isolates that had shown resist-
ance to nalidixic acid were excluded from this stage of 
the study. Donor isolates were grown in LB-ampicillin 
(60 µg/ml) broth overnight. An aliquot of a pure stock of 
the recipient strain was also grown overnight in LB broth 
but with no antibiotic. For conjugation, aliquots of each 
donor and the recipient (1 ml each) were transferred into 
fresh LB broth and incubated for 2 h. Volumes of 500 µl 
of each donor culture were each taken and mixed with an 
equal volume of the recipient culture. The mixed cultures 
were incubated for 6 h at 37 °C. Selection for transconju-
gants was carried out on MacConkey agar (MAST, UK) 
supplemented with 32  µg/ml nalidixic acid and 100  µg/
ml ampicillin [16]. Transconjugants were confirmed for 
ESBL production as previously described.
Plasmid DNA extraction
Plasmid DNA was extracted from both ESBL-producing 
donor isolates and transconjugants according to previ-
ously described methods [18, 19]. For electrophoresis, 
10 μl of each extract was mixed with 2 μl of 6X gel load-
ing dye and electrophoresed on 0.7 % agarose gel stained 
with ethidium bromide (1  μg/ml). Electrophoresis was 
carried out in 1X Tris–acetate-EDTA (TAE) buffer at 
10 V/cm for 1 h and visualized under UV transillumina-
tion [20]. The plasmid DNA samples obtained were used 
in subsequent PCRs.
Total DNA extraction
Total DNA was also extracted from ESBL-producing 
donor isolates according to the method described by [21]. 
The DNA samples obtained by this procedure were used 
in subsequent PCR procedures.
PCR for ESBL Genes
PCR amplifications of blaTEM, blaSHV and blaCTX-M 
genes were performed in 25 µl reaction mixes containing 
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25  units/ml of Taq DNA polymerase, 200  µM each of 
dATP, dGTP, dTTP and dCTP, 0.2  µM of each primer, 
1.5  mM MgCl2 and 5  µl of plasmid or total DNA tem-
plate. Amplifications were carried out with the following 
thermal cycling profile: initial denaturation for 10 min at 
94 °C followed by 35 cycles of amplification consisting of 
30 s at 94 °C, 1 min at the appropriate annealing tempera-
ture for the specific primer and 1 min at 72 °C for primer 
extension, and then 10 min at 72  °C for the final exten-
sion with a soaking step at 4 °C.
In cases where reamplifications of the previous PCR 
product were necessary, the reagent concentrations were 
modified to use only half the primer concentration used 
in the previous reaction and 1.0 µl of the previous prod-
uct as template. Primers used and their corresponding 
annealing temperatures are shown in Table 1. For electro-
phoresis, 10 µl of each PCR product were prepared and 
run as already described.
Results
A total of 137 clinical isolates belonging to E. coli, Kleb-
siella spp., Citrobacter spp., Enterobacter spp. and Pro-
teus spp. were collected for this study. Table 2 shows the 
species distribution and clinical specimens from which 
isolates were recovered.
Detection of ESBL‑producing isolates
Figure 1 shows the setup for the disc diffusion assays for 
ESBL phenotype detection. Sensitivity values were 100 % 
for cefpodoxime (CPD), 100 % for cefotaxime (CTX) and 
97.06  % for ceftazidime (CAZ). Cefpodoxime had high-
est specificity of 95.24  %, followed by CTX (94.64  %) 
and CAZ (92.98 %). Similarly, CPD recorded the highest 
PPD (92.98 %), then CTX (93.02 %) and CAZ (89.19 %). 
For NPV, CPD and CTX showed 100 %. Inhibition-zone 
size differences for Klebsiella spp. and E. coli isolates 
for all three antibiotics are presented in Fig.  2. Overall, 
52 (37.96  %) of the 132 isolates included in this study 
expressed ESBLs (Table  3). The ESBL phenotype was 
most predominant in Enterobacter spp. (62.5 %) followed 
by Citrobacter spp. (60  %). Meanwhile, Klebsiella spe-
cies comprised the majority of ESBL-producing isolates 
(42.3  %). Table  4 shows distribution of ESBL-producing 
isolates across clinical samples.
Conjugation studies
Results from the conjugation study indicated 64 % overall 
conjugability of ESBL genes amongst the ESBL-produc-
ing isolates (Table 5).
ESBL genotyping
The TEM gene was found in 25 (19.6 %) of the 127 iso-
lates with ESBL-producing phenotype. None of the 
ESBL-positive isolates had SHV- or CTX-M-type genes 
(Fig. 3). Of the 25 strains with TEM-type genes, 12 (48 %) 
transferred their ESBL phenotype in conjugation assays 
(Table  6). In 24 (0.96  %) of the 25 TEM-gene positive 
strains, the gene was detected in both plasmid and total-
DNA extracts.
Discussion
Over the last decade, many studies have demonstrated 
the presence of ESBL-mediated resistance in bacteria 
causing infections in patients [25–28]. Despite several 
reports of ESBL presence in Ghana, the characterization 
of ESBL genotypes in relation to chromosomal or plas-
mid locations—and their transferability by conjugation—
are not described.
ESBLs in study isolates
The study revealed a moderate [37.96  % (n  =  52/137)] 
prevalence of ESBL phenotype among the study isolates. 
In Table 3, the column for those that were not confirmed 
positive included all the bacteria that failed the screening 
tests as well as those that may have passed a screening 
test but failed all three confirmatory tests. The ESBL-pro-
ducing isolates were found among every genus tested.
Two observations merit attention. First, the level of 
ESBLs is comparable to that reported by other ESBL-
affected institutions in Ghana [29, 30] but higher than 
figures reported in many other reviews spanning across 
several regions [25–27]. In the African context however, 
the situation in KBTH appears to be rather moderate [13, 
14, 30]. If current trends of lack of routine ESBL-moni-
toring and lack of ESBL-control strategies continue how-
ever, it can be expected that the prevalence will rapidly 
increase. This will lead to increased treatment expenses, 
Table 1 Sequences, annealing temperatures and expected 
product sizes of primer sequences targeting the specified 
ESBL genes
Sources Bonomo et al. [22] (blaTEM), Hanson et al. [23] (blaCTX‑M), Bonomo et al. 
[24] (blaSHV)





blaTEM f: 5′‑AAA CGC TGG TGA AAG TA‑3′
r: 5′‑AGC GAT CTG TCT AT‑3′
45 720
blaSHV f: 5′‑ATG CGT TAT ATT CGC CTG  
TG‑3′
r: 5′‑TGC TTT GTT ATT CGG GCC 
AA‑3′
60 726
blaCTX‑M f: 5′‑GAC GAT GTC ACT GGC TGA 
GC‑3′
r: 5′‑AGC CGC CGA CGC TAA TAC 
A‑3′
55 499
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longer hospital stays and possibly, mortality. Second, our 
results point to ESBL-producing isolates as being present 
among various members of the family Enterobacteriaceae 
and not just Escherichia coli and Klebsiella spp. In con-
trast to the attention paid mostly to ESBLs in Escherichia 
coli and Klebsiella spp. [25–28], the study showed that 
although a minority of the isolates were non-Escheri-
chia coli and non-Klebsiella species, >40 % of these were 
ESBL-producers.
It is also noteworthy that ESBL detection was consider-
ably high among Citrobacter freundii (>50 %) and Entero-
bacter cloacae (>60  %). Though only six Proteus spp. 
isolates were included in the study, their producer preva-
lence of 16.7 % cannot be over-looked. Therefore, the prac-
tice of not investigating ESBL presence in these pathogens 
may have an adverse impact on patients who are treated 
with extended-spectrum cephalosporins. With their hyper-
motility and ability to easily dominate biofilms, ESBL-pro-
ducing Proteus spp. is a very uncomfortable prospect.
ESBL-producing strains appeared to be most common 
amongst isolates cultured from urine samples. Consider-
ing the fact that some bacteria will certainly be expelled 
in situ when urine is excreted, this has rather significant 
implications for risk of environmental contamination and 
cross-infections.
Performance of detection agents
Extent of reliability of phenotypic screening and con-
firmatory agents is needed to confidently rule out isolates 
that do not pass screening and/or confirmatory tests. 
Both cefpodoxime and cefotaxime had 100 % sensitivity 
scores and 100 % negative predictive value (NPV) scores. 
After comparing specificity and positive predictive value 
(PPV) scores however, it was evident that cefotaxime had 
a lesser likelihood of refusing a possible-positive than 
cefpodxime. It is generally accepted that cefpodoxime 
is the best single agent for ESBL detection [31]. From 
these results however, cefotaxime, with its slightly lower 
Table 2 Distribution of study isolates according to clinical sources
Though only one instance of infection was observed from three CSF samples tested, it was separated due to the clinical significance of infection in the normally sterile 
cerebrospinal region
CSF cerebrospinal fluid, HVS high vaginal swab
a Refers to miscellaneous clinical sources (wound swabs, pus, aspirates, ear swabs)
Isolate Clinical source Number of  
species
Urine Blood Sputum CSF HVS Othera Total %
Citrobacter spp. 2 1 6 0 1 0 10 7.3
Enterobacter spp. 2 5 1 0 0 0 8 5.8
Escherichia coli 42 9 7 1 3 7 69 50.4
Klebsiella spp. 23 6 8 0 4 3 44 32.1
Proteus spp. 1 0 4 0 1 0 6 4.4
Total 70 (51.1 %) 21 (15.3 %) 26 (19.0 %) 1 (0.7 %) 9 (6.6 %) 10 (7.3 %) 137 100
Fig. 1 Appearance after over‑night incubation for ESBL phenotyping of (a) an ESBL‑positive strain and b an ESBL‑negative strain. Plate a shows an 
example of what was taken as a positive ESBL test result. Plate b shows an example of a negative ESBL test result. In both cases, cefpodoxime was 
used only to screen and not in confirmation. Cefotaxime and ceftazidime were used in both screening and confirmation. CPD cefpodoxime 10 µg, 
CPD/CLV cefpodoxime 10 µg + clavulanate 10 µg, CTX cefotaxime 30 µg, CTX/CLV cefotaxime 30 µg + clavulanate 10 µg, CAZ ceftazidime 30 µg, 
CAZ/CLV ceftazidime 30 µg + clavulanate 10 µg
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specificity score but higher positive predictive value 
score, performed just as well as, if not better than, cef-
podoxime. Data of this nature are very important since 
for a given study involving large numbers of samples, one 
cannot screen all collected isolates by genotypic methods 
which are the gold standard in ESBL detection.
Unusual inhibition zone patterns should however be 
treated on a case-by-case basis.
Fig. 2 Inhibition zone chart for Klebsiella spp. and E. coli isolates. Zone differences observed between screening and confirmatory tests using each 
of the screening antibiotics alone and in its appropriate combination with clavulanate for confirmation. CPD cefpodoxime, CTX cefotaxime, CAZ 
ceftazidime. Region a zone differences for ESBL‑positive phenotype. Region b zone‑differences for ESBL‑negative phenotype. Region (c) unusual 
zone differences
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Inferences from inhibition zones
Comparing the cefpodoxime zone size differences rep-
resented in Fig.  2 to data from the British society for 
antimicrobial chemotherapy [32], certain implications 
were realised. It was seen that the patterns of size differ-
ences represented in both figures were quite different. 
In the reference data, zone differences of the major-
ity of ESBL-producer isolates fell between the ranges of 
6–26  mm whereas from this study, zone differences fell 
between 13–30  mm with the majority ranging from 18 
to 30 mm. The relatively higher zone sizes realized from 
this data may be indicative of differences in plasmid copy 
numbers and activity profiles of the enzymes as well as 
differences in permeability characteristics of the isolates 
from the two different localities.
Two Klebsiella isolates had cefpodoxime zone size dif-
ferences that were in the negatives; −1 and −3 (Fig. 2). 
The lack of synergistic effect with the addition of clavu-
lanate might suggest that they produce AmpC enzymes. 
However, they both tested screen-negative with each 
antibiotic used, uncharacteristic of AmpC-producing 
strains. Comparing to the reference data, those isolates 
were likely to produce K1 β-lactamases. The K1 enzymes 
are a family of β-lactamses, encoded by chromosomal 
genes, and which are presently thought to be unique to 
Klebsiella oxytoca. The two isolates however had cor-
responding ceftazidime zone-size differences of −7 
and 1 mm. This implies that any K1 presence in them is 
unlikely since ceftazidime is notably susceptible to K1 
enzymes. Also, the activity of K1 enzymes on ceftazidime 
is greatly diminished with the addition of clavulanate [33, 
34]. Both isolates were amongst those most susceptible 
to the screening agents used, including ceftazidime, but 
were obviously not affected by clavulanate synergy. Cur-
rently, the only β-lactamase class that fits this profile 
of decreased affinity for β-lactam substrates and non-
inhibition by clavulanate is the mutants of the inhibitor-
resistant TEMs (IRTs) which belong to class A, subgroup 
2br. The 2br subgroup contains the inhibitor-resistant 
TEM-type enzymes that evolved from the classical 
TEMs by acquiring the substitutions M69 V and N276D 
[29]. Derivatives of these enzymes are the complex TEM 
mutants (CTMs) that combine inhibitor-resistance with 
decreased affinity for cephalosporins [35].
A few isolates (4 for cefpodoxime, 3 for cefotaxime 
and 5 for ceftazidime) were screen-positive but failed 
the confirmatory tests, with 2 strains common to cefpo-
doxime and cefotaxime and 1 strain being common to all 
three antibiotics. This kind of phenotype, though typi-
cal of ampC-producers, may also be expressed by strains 
with CTMs, high levels of the TEM-1 enzyme and OXA-
type ESBLs.
An interesting observation was one Klebsiella isolate 
which was clearly screen-positive with cefpodoxime, 
tested screen-negative for ceftazidime but was affected 
by clavulanate synergy with ceftazidime. Screening by 
Table 3 ESBL prevalence amongst study isolates
ESBL prevalence was determined using MAST D52C combined discs by the 
Kirby‑Bauer method of antibiotic susceptibility testing
a The column for “not confirmed ESBL‑positive” includes isolates that failed 
screening tests as well as those isolates that may have passed the screening 
test(s) but failed confirmatory tests







Citrobacter spp. 4 6 (60 %) 11.5
Enterobacter spp. 3 5 (62.5 %) 9.6
Escherichia coli 51 18 (26.1 %) 34.6
Klebsiella spp. 22 22 (50.0 %) 42.3
Proteus spp. 5 1 (16.7 %) 1.9
Total 85 52 (37.9 %) 100
Table 4 Distribution of  ESBL-producing strains according 
to clinical sources
HVS high vaginal swab, CSF cerebrospinal fluid
a Refers to miscellaneous clinical sources (wound swabs, pus, aspirates, and ear 
swabs)
Clinical source Sample size ESBL phenotype present
Number % of total number 
of ESBL‑producers
Urine 70 31 (44.3 %) 59.6
Blood 21 9 (42.9 %) 17.3
CSF 1 0 (0) 0
HVS 9 3 (33.3 %) 5.8
Sputum 26 5 (19.2 %) 9.6
Othera 10 4 (40 %) 7.7
Total 137 52 100
Table 5 Conjugabilities of ESBL-producer phenotype from  
isolates confirmed for ESBL production
ESBL‑positive study isolates were conjugated to nalidixic acid‑resistant E. coli 
K‑12. Selection of transconjugants was done on MacConkey agar (MAST, UK) 
supplemented with ampicillin and nalidixic acid




Klebsiella pneumoniae 22 19 86.4
Escherichia coli 18 9 50.0
Enterobacter spp. 5 2 40.0
Citrobacter spp. 4 1 25.0
Proteus spp. 1 1 100
Total 50 32 64
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ceftazidime alone would have led to the isolate being 
ruled as an ESBL non-producing strain. However, the 
observed synergy upon addition of clavulanate suggests, 
besides the possibility of AmpC-production, the presence 
of other β-lactamase types that are susceptible to the 
inhibitor.
It is seen from Fig. 2 that from 5 to 15 mm in region 
(a), inhibition of cefotaxime hydrolysis by clavulanate is 
not shown. This is a likely indication of the presence of 
CTX-M enzymes which preferentially hydrolyse cefo-
taxime relative to cefpodoxime and ceftazidime. Like all 
other ESBLs, CTX-M enzymes are susceptible to inhibi-
tion by clavulanate. The effect of clavulanate synergy with 
cefpodoxime and ceftazidime is seen but since CTX-M’s 
normally hydrolyse these with relatively lower turn-over 
rates, the zone size differences there are not as large as 
for cefotaxime which the enzymes would hydrolyse with 
greater efficiency in the absence of clavulanate.
Conjugation study
In the present study, about 63  % conjugability was 
observed, higher than the 38.7 % reported in Cameroon 
by [36]. In contrast to the report by [37] where E. coli 
showed higher ESBL conjugability than Klebsiella spp., 
Klebsiella had the highest rate of 86.4  % followed by E. 
coli’s 50  % (Table  5). This pattern of results may stem 
from the fact that Klebsiellae have been found to fre-
quently harbor plasmids bearing blaSHV -type genes, and 
considering the usual sizes of blaTEM—(less than 80 kb) 
and blaSHV—(from about 80 kb to up to 350 kb in some 
Klebsiella isolates) bearing plasmids, the latter are prob-
ably more likely to be conjugable.
DNA extraction and PCR
All isolates positive for ESBL-production were selected 
for DNA extraction. Attempts at linearization of plas-
mids using PstI, HindIII and EcoRI restriction enzymes 
always failed. A plasmid which consistently appeared 
in the 22 kb position (data not shown) was found to be 
present in some of the plasmid extracts in which TEM 
genes were detected. Further resolution of the 22 kb band 
showed that it consisted of two clearly distinct bands 
placed closely together. All the plasmid extracts had 
the lower band. Plasmid preparations from a few of the 
transconjugants showed only the lower band, suggesting 
Fig. 3 Bands observed after reamplification of previous PCR product with the TEM family‑specific primers. PCR products were resolved on 2 % 
agarose gel stained with 1 µg/ml ethidium bromide at 100 V for 30 min. The gel was photographed under UV illumination. Lane M 1 kb plus DNA 
ladder, Lanes 2, 4, 5, 7, 8, 10 PCR product from showing amplified TEM gene with band position at 720 bp, Lane 6 TEM‑3‑producing E. coli NCTC 
13351, Lanes 1, 3, 9 PCR product with no amplification
Table 6 Numbers of detected conjugative TEM genes
The TEM primer produced PCR amplification product in DNA extracts from 25 
of the ESBL‑positive isolates. Verification of which of these genes had been 
transferred by conjugation was obtained by comparing this data to results of 
PCR on plasmid‑DNA extracts from the transconjugants
Isolate TEM Number that had  
transferred by conjugation
Citrobacter spp. 0 0
Enterobacter spp. 1 0
Escherichia coli 11 3
Klebsiella spp. 12 8
Proteus spp. 1 1
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that the higher band may have been a non-conjugable 
plasmid species.
DNA extracted by a Promega Plus SV Miniprep DNA 
kit and [20] were used for PCR with blaTEM, blaSHV 
and blaCTX-M primers. Initial PCR rounds on control 
isolates showed amplification products for blaTEM but 
none for blaSHV and blaCTX-M positive controls (data 
not shown). Generally, the blaTEM products required re-
amplification to be clearly visible (Fig.  3). A total DNA 
extract belonging to an Enterobacter spp. isolate pro-
duced amplification product but nothing was observed 
with its corresponding plasmid extract. This suggested 
that the detected gene may have been chromosomal. 
With the Klebsiella spp. and E. coli isolates that produced 
amplicons with both DNA extracts, there is at least a 
plasmid-borne blaTEM gene present even if there may 
be others that are chromosomal. Particularly with the 
Proteus spp. DNA sample, the detection made with the 
total-DNA extract was notably very faint relative to that 
from its plasmid extract. Due to the fact that any plasmid 
template present would be very dilute in the total-DNA 
preparation, this strongly suggested again that the gene 
detected by PCR may have been plasmid-borne in the 
Proteus isolate.
Plasmid mediation and conjugability
TEM-producing isolates that did not have the 22 kb plas-
mid included 2 E. coli, 1 Enterobacter and 1 Proteus iso-
late. This may have been a TEM-bearing plasmid since it 
was common to 84 % of the isolates in which TEM was 
detected. Judging from its size however, it was unlikely 
to be conjugative and this had been demonstrated by 
its absence in the plasmid extracts from the transconju-
gants. It was unlikely also to be mobilisable since it was 
not observed in any of the transconjugants tested. [38] 
has however previously reported the successful conjuga-
tion of a 10 kb ESBL-associated resistance determinant. 
The Proteus isolate had transferred its phenotype during 
the conjugation study (Table 6), suggesting that the gene 
it carried was on a mobilisable plasmid. The proportion 
of ESBL conjugability reported here also suggests that 
precautions should be taken to minimise the possibil-
ity of horizontal transfer of ESBL genes as well as clonal 
spread as reported by [39].
Conclusions
Detection level of ESBL-producing strains amongst the 
isolates studied was 37.96  % (n  =  137). It is important 
that subsequent work carried out on ESBL-producing 
strains should take ampC β-lactamase detection as well 
as influence from other types of β-lactamases that may be 
present into account. This is because as more and more 
isolates begin to concomitantly produce these enzymes, 
interactions between them will make antibiograms of 
the isolates rather difficult to interpret. In the majority 
of cases, ESBL-producing bacteria in the hospital could 
transfer the phenotype by conjugation. Interpretative 
reading of the inhibition-zone chart suggests that other 
types of β-lactamases such as inhibitor-resistant TEMs 
(IRTs) and ampCs might have been present amongst the 
isolates. These need to be investigated.
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